We’re moving people out of the criminal justice system instead of into it, we’re saving resources, we’re saving taxpayer ...

AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about ...

AbbVie Inc (NYSE: ABBV) saw its stock fall nearly 13% after reporting disappointing mid-stage trial results for emraclidine, ...

Jacob Ballon, MD, MPH, of Stanford University in California, discussing research evaluating the impact of different antipsychotics on the cognitive symptoms of schizophrenia. "There is no clear ...

The S&P 500 Index ($SPX) (SPY) Monday closed up +0.10%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +0.69%, and ...

The S&P 500 Index ($SPX) (SPY) today is up +0.21%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +1.02%, and the Nasdaq ...

The most common side effects of INVEGA HAFYERA® include: injection site reactions, weight gain, headache, upper respiratory ...

Shares of AbbVie (ABBV) are sinking on Monday after the company said two mid-stage trials of its investigative treatment for adults with schizophrenia missed their primary endpoints. AbbVie’s ...

Researchers have developed a potential diagnostic tool for schizophrenia by observing how patients process conflicting information.

Among individuals with schizophrenia, the risk for natural-cause mortality was increased in those with reduced cognitive functioning.

Teva Pharmaceuticals’ TEV-‘749 (olanzapine) has shown statistical improvement in schizophrenia symptoms in a Phase III trial. The Phase III SOLARIS trial (NCT05693935) demonstrated ...

As she put it: There’s a little bit of schizophrenia going on, but it doesn’t last as long as it used to. Considering Kelly Reilly didn't appear to spend any part of that conversation ...